$77.3 Million is the total value of KPCB XV Associates, LLC's 4 reported holdings in Q1 2022. The portfolio turnover from Q4 2021 to Q1 2022 was 33.3% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| TWLO | Buy | Twilio Inc. | $31,322,000 | -36.8% | 190,047 | +1.0% | 40.53% | +3.7% |
| RAPT | Rapt Therapeutics, Inc. | $28,522,000 | -40.1% | 1,297,063 | 0.0% | 36.91% | -1.8% | |
| ATRA | Atara Biotherapeutics, Inc. | $17,434,000 | -41.1% | 1,876,650 | 0.0% | 22.56% | -3.3% | |
| AUGX | New | Augmedix, Inc | $2,000 | – | 708 | +100.0% | 0.00% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2022-05-13
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| Twilio Inc. | 8 | Q3 2022 | 54.3% |
| Rapt Therapeutics, Inc. | 8 | Q3 2022 | 43.7% |
| Atara Biotherapeutics, Inc. | 8 | Q3 2022 | 27.0% |
| Upstart Holdings, Inc. | 3 | Q2 2021 | 42.4% |
| Augmedix, Inc. | 2 | Q2 2022 | 0.0% |
View KPCB XV Associates, LLC's complete holdings history.
Latest filings
| Type | Filed |
|---|---|
| 13F-HR | 2022-10-26 |
| 13F-HR | 2022-07-21 |
| 13F-HR | 2022-05-13 |
| 13F-HR | 2022-02-14 |
| 13F-HR | 2021-10-25 |
| 13F-HR | 2021-07-28 |
| 13F-HR | 2021-05-13 |
| 13F-HR | 2021-02-16 |
| 4 | 2020-10-20 |
| 4 | 2020-09-11 |
View KPCB XV Associates, LLC's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.